Phase 4Completed
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone (REALIZE-K)
Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction and Receiving Spironolactone
- Sponsor
- AstraZeneca (Industry)
- Enrollment
- 366 enrolled
- Conditions
- Hyperkalaemia; Heart Failure With Reduced Ejection Fraction
- Interventions
- Sodium zirconium cyclosilicate; Placebo; Spironolactone
- Ages
- adults, older adults
- Registry
- NCT04676646, EUCTR2020-003312-27
Full record on ClinicalTrials.gov
From the registry
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue therapy for hyperkalaemia (HK).
Primary outcomes
- Participants Who Achieved Response, Defined as Serum Potassium (sK+) Within 3.5 to 5.0 mEq/L, Spironolactone Greater Than or Equal to 25 mg Daily, no Rescue Therapy for Hyperkalaemia
History
Results first posted
Last registry update
Primary completion
Started
Registered